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did not show any evidence of intraabdominal disease.
Case
A 62-year-old postmenopausal woman presented to the emergen-
cy room after a fall that resulted in acute exacerbation of right shoul-
der pain. She ﬁrst noticed this pain three weeks prior, but could not
identify any inciting factors. In the emergency room, an X-ray wasIntroduction
tomography (CT) scan of the chest, abdomen, and pelvis was obtained
and revealed multiple pulmonary nodules, necrotic-appearing mediasti-Uterine cancer is the most common form of gynecologic cancer in
the United States. It is estimated that 47,130 new cases will be diag-
nosed and 8010 uterine cancer related deaths will occur during
2012 in the United States (Siegel et al., 2012). The most common his-
tological type is endometrioid adenocarcinoma, comprising 80% of
cases (Clement and Young, 2002). Less commonly seen are serous,
clear cell, and undifferentiated carcinomas. Patients with undifferen-
tiated carcinomas may have a coexisting low-grade endometrioid
adenocarcinoma, which suggests a process of dedifferentiation and
classiﬁes these tumors as a dedifferentiated (undifferentiated)
endometrioid adenocarcinoma (Silva et al., 2006). The low-grade com-
ponent in these tumors is typically grade 1 or 2 by the Federation of Gy-
necology and Obstetrics (FIGO) grading system. Dedifferentiated
endometrioid adenocarcinomas may often be mistaken for more com-
mon forms of endometrial cancer and are therefore thought to be
under-recognized. There is still a lack of information regarding its typical
clinical presentation and clinical course. Reports to date suggest that this
is an aggressive form of cancer even when the undifferentiated compo-
nent represents only 20% of the entire neoplasm (Silva et al., 2006). We
describe a case of dedifferentiated endometrioid adenocarcinoma thatjhmi.edu (I.-M. Shih),
Inc. Open access under CC BY-NC-SA licenseobtained that showed a proximal humeral facture with lytic lesions
in the surrounding bone (Fig. 1). She was placed in a sling and
dischargedwith outpatient follow-up. As part of herworkup, a computed
nal and hilar lymph nodes, a left adrenal nodule, a mass within the T10
vertebral body with epidural extension and spinal cord compression,
and multiple bony lytic lesions. Bony lesions were noted throughout
the T1 and T10 vertebral bodies, left ileum, right ileum, left femoral
head, and left acetabulum. The pelvis was notable for a ﬁbroid uterus,
butwas otherwise unremarkable. Therewas no pelvic lymphadenopathy
or ascites.
One week later, she presented to the emergency room with rapid
onset of lower extremity weakness. She was admitted with a diagno-
sis of spinal compression and initiated on dexamethasone to prevent
further neurologic compromise. Magnetic resonance imaging (MRI)
demonstrated a large T11 lesion with extensive epidural extension,
a T2 lesion expanding into the prevertebral and ventral epidural
space, and numerous other lesions throughout her spinal column
(Fig. 2). Neurosurgery took her to the operating room for decompres-
sion and performed a T10–T12 laminectomy, tumor resection with
T11 vertebrectomy, T9–L1 fusion and reconstruction with titanium
cage and bone matrix allograft.
The pathology specimen showed a poorly differentiated adenocarci-
noma. It was strongly positive for estrogen receptors, progesterone re-
ceptors, and Pax 8, suggesting an endometrial or breast cancer. On
further interview, the patient reported ﬁve months of intermittent vag-
inal bleeding and a left breast mass. Bilateral mammography was nega-
tive. Pelvic ultrasound revealed ﬁbroids with poor visualization of the
endometrial lining. Pathology from dilation and curettage was notable
for a well-differentiated endometrioid carcinoma and an associated un-
differentiated carcinoma, suggesting dedifferentiated endometrioid ad-
enocarcinoma (Fig. 3). Histopathological and immunostaining features.
Fig. 1. Shoulder X-ray obtained on initial presentation showing a proximal humeral
facture with lytic lesions in the surrounding bone (arrow).
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specimen from T11. CA-125 was elevated to 264.
Two weeks after her initial surgery, she began radiation therapy.
Over the course of two weeks, she received 3000 cGy of radiation ther-
apy in 10 fractions to C5–T2 and the right humerus. Due to inadequateFig. 2.Magnetic resonance T2 STIR image showing metastatic lesions at the C7, T2 and
T11 vertebral bodies with epidural extension (labeled, arrows). Note this has resulted
in a pathologic compression fracture at C7 and mild cord compression at T11.healing at the site of spinal fusion, radiation therapy to T10–T12 was
deferred until six weeks after her initial surgery, after which she re-
ceived another 3,000 cGy in 10 fractions. She remained wheelchair
bound and her Gynecological Oncology Group performance status was
estimated to be 3–4. This precluded her from chemotherapy and she
was therefore started on a regimen of megace alternating with tamoxi-
fen (Fiorica et al., 2004). Due to leukocytosis and deep venous thrombo-
ses, she was readmitted to the hospital 6 weeks after initiating hormonal
therapy. Imaging studies showed progression of disease, including a new
compression of the T2 vertebral body and widespread nodal and pulmo-
nary metastatic disease. CA-125 had risen from 264 to 789. The patient
and her family elected to discontinue treatment and transfer to home
hospice given the rapid progression of disease.
Comment
Endometrioid adenocarcinoma of the uterus is a frequent neo-
plasm and is usually found in pure form with a favorable prognosis.
Undifferentiated carcinomas are less common and thought to occur
in only 9% of endometrial carcinomas (Altrabulsi et al., 2005). Until
a case series published by Silva et al. (2006), the association of
these two types of tumors had received little attention in the litera-
ture and was thought to have little clinical signiﬁcance. However,
more widespread recognition of this tumor is important because it
likely has a poor prognosis. The series described by Silva et al. is still
the largest case series to date, and provided follow-up information for
12 patients with dedifferentiated endometrioid adenocarcinoma of the
uterus. Of these patients, 7 were dead of disease (3–60 months), 4
were alive with progression of disease (6–8 months) and 1waswithout
any evidence of disease (104 months). Irrespective of the amount of un-
differentiated carcinoma present, these neoplasms exhibited aggressive
behavior. Furthermore, histologic changes seen in recurrent tumors sug-
gested that the presence of an undifferentiated carcinoma admixedwith
endometrioid adenocarcinomawas a result of dedifferentiation (Silva et
al., 2006). Based onmutational analysis of several genes including TP53,
we have shown the clonal relationship between the well-differentiated
endometrioid carcinoma and the undifferentiated carcinoma from the
same patient in the majority of cases (Kuhn, unpublished). These ﬁnd-
ings are consistent with those found in our case. Not only were the
endometrioid adenocarcinoma of the endometrium and the undifferen-
tiated carcinoma in our patient admixed, but the histology from theme-
tastases were most consistent with the undifferentiated component
derived from the endometrial sample. Although undifferentiated carci-
nomas have been reported to lose ER and PR expression, expression of
ER and PR in both undifferentiated carcinoma and well-differentiated
endometrioid carcinoma suggests that de-differentiation during tumor
progression does not affect ER and PR expression in this particular case
(Tafe et al., 2010 Jun). As a result, retained ER and PR expression in un-
differentiated carcinomamay serve as tissue biomarkers to suggest that
the metastatic lesions are derived from either breast or gynecologic
origin.
Given subtle differences in histologic appearance, dedifferentiated
endometrioid adenocarcinoma may be mistaken for a high-grade
endometrioid adenocarcinoma, malignant mixed mullerian tumor,
or unclassiﬁed sarcoma. In the FIGO system, tumors are graded by
the proportion of solid endometrioid components within a tumor,
without further distinction based on histologic features. As a result,
dedifferentiated endometrioid adenocarcinoma may be incorrectly
classiﬁed as a FIGO grade 3 endometrioid adenocarcinoma. This may
explain why the 5-year survival for grade 3 endometrioid carcinoma,
ranges so widely, from 40 to 70% (Silva et al., 2007). In the Silva et al.,
2006 analysis, many cases of dedifferentiated tumors were initially
designated as FIGO grade 2, but exhibited unusually rapid progression
(Silva et al., 2006). The implications of this may be profound, given
the prognostic, and therefore potential treatment, differences be-
tween FIGO grade 2, grade 3, and dedifferentiated tumors.
Fig. 3. Morphological features of the endometrial curettage specimen (hematoxylin and eosin stain). A. A low magniﬁcation demonstrates both low-grade (glandular pattern) and
high-grade (solid pattern) components of the carcinoma. B. The low-grade carcinoma exhibits the classical glandular pattern, forming a conﬂuent pattern. C. A high magniﬁcation
demonstrates tumor cells forming glands. D. A high magniﬁcation view shows solid growth of the high-grade carcinoma without forming glands. The tumor cells appear poorly
differentiated as compared to the tumor cells in C.
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sizes, the majority of metastases are comprised of only the undiffer-
entiated component. Our case exhibits the same behavior, but is
unique in the unusual distribution of bone metastases with lack of
involvement in pelvic structures. In endometrial cancer, when metas-
tases occur, they are typically found in the lymph nodes, ovary, omen-
tum, peritoneum, liver, or lung. Bone metastases are less common
and are estimated to occur in less than 15% of women with metastatic
endometrial cancer (Albareda et al., 2008). However, data are limited
to single-institution case reports. Even in dedifferentiated endometrioid
adenocarcinoma, most metastases occurred in the pelvis or abdomen.
There were no reported cases of bony metastases, leave alone those that
initially presented with pathologic fractures (Silva et al., 2006). Vizzelli
et al. (2012)most recently compiled cases of endometrial cancer present-
ing as bonemetastases and noted the bones of the appendicular skeleton,
such as the tibia, femur, calcaneus, and ﬁbular and humerus, to be
the most typical bony structure affected. Based on a PubMed search
from 1950 to the present, using keywords including “endometrial neo-
plasms” and “bone neoplasms”, there have only been 4 prior cases of
endometrial cancer presenting with spinal metastases, and none in com-
bination with lytic lesions in the humerus, as seen in the current case.
In conclusion, two lessons can be gleaned from this case. The ﬁrst
is that the recognition of dedifferentiated endometrioid adenocarci-
noma of the uterus is important because it has prognostic and poten-
tially therapeutic implications. A focus of undifferentiated carcinoma
may be confused with the solid component in an endometrioid ade-
nocarcinoma. This would erroneously result in the diagnosis of a
less aggressive tumor, and potentially result in providing suboptimal
therapy. Second, although bony metastases are rare in endometrial
cancer, it is important to consider when a patient with endometrial
cancer presents with joint pain.Consent
Written informed consent was obtained from the patient for pub-
lication of this case report and accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this
journal on request.
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